MDxHealth Target Cut to $2.00, Citing Dilution From Share Offering

BTIG lowered its price target for MDxHealth SA from $4.00 to $2.00. The firm maintained its Buy rating on the stock.

This adjustment follows second-quarter results and a $20 million registered direct offering. The lower target primarily reflects the increased share count resulting from the capital raise.

BTIG analysts project the company will return to positive adjusted EBITDA by the fourth quarter of 2026. While shares have declined 80% over the past six months, the stock has shown a slight recovery from its recent offering price.